All contrarian strategies seem perfectly clear in hindsight. What appears as brilliance one day can look like naïveté the next. Dr Reddy's Laboratories finds itself in this dilemma. While most foreign firms flee Russia's regulatory and geopolitical challenges, Dr Reddy's sprints in the opposite direction.The company announced a ₹5.65 billion fresh investment in Russian operations, even as US President Donald Trump imposes 25% tariffs on Indian goods and another 25% penalty for ties with Moscow. The Russian investment follows impressive 17% year-on-year revenue growth as Western competitors fled, creating market share opportunities for affordable generics.
.png)
